YounossiZM, KoenigAB, AbdelatifD, et al.: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64:73–84.
2.
ChalasaniN, YounossiZ, LavineJE, et al.: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67:328–357.
3.
European Association for the Study of theL, European Association for the Study ofD, European Association for the Study ofO: EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016; 64:1388–1402.
4.
PerumpailBJ, KhanMA, YooER, et al.: Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017; 23:8263–8276.
CusiK, OrsakB, BrilF, et al.: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med, 2016; 165:305–315.
7.
BrowningJD, SzczepaniakLS, DobbinsR, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004; 40:1387–1395.
8.
DysonJK, AnsteeQM, McPhersonS: Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol, 2014; 5:211–218.
9.
MofradP, ContosMJ, HaqueM, et al.: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 2003; 37:1286–1292.
10.
AdamsLA, SandersonS, LindorKD, AnguloP: The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol, 2005; 42:132–138.
11.
GuhaIN, ParkesJ, RoderickPR, et al.: Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut, 2006; 55:1650–1660.
12.
UslusoyHS, NakSG, GultenM, BiyikliZ: Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol, 2009; 15:1863–1868.
DasarathyS, DasarathyJ, KhiyamiA, et al.Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol, 2009; 51:1061–1067.
15.
RogierJ, RoulletS, CornélisF, et al.: Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio. Liver Transpl, 2015; 21:690–695.
16.
RockeyDC, CaldwellSH, GoodmanZD, et al.Liver biopsy. Hepatology, 2009; 49:1017–1044.
17.
KleinerDE, BruntEM, Van NattaM, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005; 41:1313–1321.
18.
BedossaP, PoitouC, VeyrieN, et al.: Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology, 2012; 56:1751–1759.
19.
American Diabetes Association: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019. Diabetes Care, 2019; 42(Suppl 1):S34–S45.
20.
AnguloP, HuiJM, MarchesiniG, et al.: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45:846–854.
21.
ShahAG, LydeckerA, MurrayK, et al.: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009; 7:1104–1112.
22.
Cichoz-LachH, CelinskiK, Prozorow-KrolB, et al.: The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit, 2012; 18:CR735–CR740.
23.
DowmanJK, TomlinsonJW, NewsomePN: Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2011; 33:525–540.
24.
De SlivaS, LiW, KemosP, et al.: Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian Descent. Gut, 2017; 66(Suppl 2):PWE–075.
25.
BertotLC, JeffreyGP, de BoerB, et al.: Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int, 2018; 38:1793–1802.
26.
SigristRMS, LiauJ, KaffasAE, et al.: Ultrasound elastography: review of techniques and clinical applications. Theranostics, 2017; 7:1303–1329.
27.
SiddiquiMS, VuppalanchiR, Van NattaML, et al.: Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019; 17:156–163. e152.
28.
LoombaR, WolfsonT, AngB, et al.: Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology, 2014; 60:1920–1928.
29.
McPhersonS, StewartSF, HendersonE, et al.: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010; 59:1265–1269.
30.
Vilar-GomezE, Martinez-PerezY, Calzadilla-BertotL, et al.: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 2015; 149:367–378.
31.
PromratK, KleinerDE, NiemeierHM, et al.: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH). Hepatology, 2010; 51:121–129.
32.
HarrisonSA, FechtW, BruntEM, Neuschwander-TetriBA: Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology, 2009; 49:80–86.
33.
WongVW, ChanRS, WongGL, et al.: Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol, 2013; 59:536–542.
34.
MardinogluA, WuH, BjornsonE, et al.: An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans. Cell Metab, 2018; 27:559–571. e555.
35.
ErrazurizI, DubeS, SlamaM, et al.: Randomized controlled trial of a MUFA or fiber-rich diet on hepatic fat in prediabetes. J Clin Endocrinol Metab, 2017; 102:1765–1774.
36.
MathurinP, HollebecqueA, ArnalsteenL, et al.: Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology, 2009; 137:532–540.
37.
ForceABET, CommitteeAT, Abu DayyehBK, et al.: ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc, 2015; 82:425–438. e425.
38.
KlebanoffMJ, CoreyKE, ChhatwalJ, et al.: Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis. Hepatology, 2017; 65:1156–1164.
MacauleyM, HollingsworthKG, SmithFE, et al.: Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab, 2015; 100:1578–1585.
41.
BrilF, KalavalapalliS, ClarkVC, et al.Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol, 2018; 16:558–566. e552.
42.
BrilF, CusiK: Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care, 2017; 40:419–430.
43.
YauH, RiveraK, LomonacoR, CusiK: The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep, 2013; 13:329–341.
44.
TuccoriM, FilionKB, YinH, et al.: Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ, 2016; 352:i1541.
45.
LewisJD, HabelLA, QuesenberryCP, et al.: Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA, 2015; 314:265–277.
46.
DavidsonMB: Pioglitazone (Actos) and bladder cancer: legal system triumphs over the evidence. J Diabetes Complications, 2016; 30:981–985.
47.
SchurksM, GlynnRJ, RistPM, et al.: Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ, 2010; 341:c5702.
48.
KleinEA, ThompsonIMJr., TangenCM, et al.: Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 2011; 306:1549–1556.
49.
PerazzoH, DufourJF: The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int, 2017; 37:634–647.
50.
SumidaY, YonedaM: Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol, 2018; 53:362–376.
51.
RatziuV, HarrisonSA, FrancqueS, et al.: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, 2016; 150:1147–1159. e1145.
